ArticleClinical research in cardiology : official journal of the German Cardiac Society2023
Paclitaxel drug-coated balloon-only angioplasty for de novo coronary artery disease in elective clinical practice.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 5 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- A systematic review and meta-analysis of the use of drug-coated balloon angioplasty for treatment of both de novo and in-stent coronary chronic total occlusions.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Pooled it
- Drug-Coated Balloons Versus Other Percutaneous Coronary Intervention Strategies in De Novo Coronary Artery Disease: A Systematic Review, Meta-Analysis With Trial Sequential Analysis.Cardiovascular therapeutics · 2026Pooled it
- Drug-coated balloon versus drug-eluting stent for treating de novo large vessel coronary artery disease: a systematic review and meta-analysis of 13 studies involving 2888 patients.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Pooled it
- Drug coated balloon angioplasty for de novo coronary lesions in large vessels: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Comparison of Efficacy and Safety Between Drug-Coated Balloons Versus Drug-Eluting Stents in the Treatment of De Novo Coronary Lesions in Large Vessels: A Study-Level Meta-Analysis of Randomized Control Trials.Cardiovascular drugs and therapy · 2024Pooled it
- Clinical application and expansion of paclitaxel-coated balloons in coronary atherosclerotic disease.World journal of cardiology · 2026Review
- A Comparison of a Drug Coated Balloon With Drug Eluting Stent Strategy for Treating Coronary Bifurcation Lesions.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026Article
- Assessment of Paclitaxel Drug-Coated Balloon-Only Angioplasty for Multivessel Coronary Artery Disease.Journal of clinical medicine · 2025Article
- Validation of complex PCI criteria in drug-coated balloon angioplasty.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Observational
- Advances in drug-coated balloons for the treatment of coronary artery de novo large-vessel lesions.The Journal of international medical research · 2025Review
- Assessment of Paclitaxel Drug-Coated Balloon-Only Angioplasty for Stent Thrombosis: SPARTAN-ST Study.Journal of cardiovascular development and disease · 2025Article
- Drug-Coated Balloons for Coronary Interventions: A Focused Review.Methodist DeBakey cardiovascular journal · 2025Review
- Safety aspects ofFrontiers in cardiovascular medicine · 2025Article
- Coronary Artery Dissection Series - Back to the Future II: The ARM Strategy (Avoid, Recognize and Manage Dissections) in Drug-coated Balloon Angioplasty.Heart international · 2025Article
- One-Month Duration Compared with Twelve-Month Duration of Dual Antiplatelet Therapy in Elective Angioplasty for Coronary Artery Disease: Bleeding and Ischaemic Outcomes.Journal of clinical medicine · 2024Article
- A New Frontier for Drug-Coated Balloons: Treatment of "De Novo" Stenosis in Large Vessel Coronary Artery Disease.Journal of clinical medicine · 2024Review
- Efficacy and risks of drug-coated balloon treatment for coronary artery disease: A meta-analysis.Heliyon · 2023Article
- Circulating intermediate monocytes CD14++CD16+ are increased after elective percutaneous coronary intervention.PloS one · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe aimed to investigate the safety of drug-coated balloon (DCB)-only angioplasty compared to drug-eluting stent (DES), as part of routine clinical practice.
backgroundThe recent BASKETSMALL2 trial demonstrated the safety and efficacy of DCB angioplasty for de novo small vessel disease. Registry data have also demonstrated that DCB angioplasty is safe; however, most of these studies are limited due to long recruitment time and a small number of patients with DCB compared to DES. Therefore, it is unclear if DCB-only strategy is safe to incorporate in routine elective clinical practice.
methodsWe compared all-cause mortality and major cardiovascular endpoints (MACE), including unplanned target lesion revascularisation (TLR) of all patients treated with DCB or DES for first presentation of stable angina due to de novo coronary artery disease between 1st January 2015 and 15th November 2019. Data were analysed with Cox regression models and cumulative hazard plots.
resultsWe present 1237 patients; 544 treated with DCB and 693 treated with DES for de novo, mainly large-vessel coronary artery disease. On multivariable Cox regression analysis, only age and frailty remained significant adverse predictors of all-cause mortality. Univariable, cumulative hazard plots showed no difference between DCB and DES for either all-cause mortality or any of the major cardiovascular endpoints, including unplanned TLR. The results remained unchanged following propensity score-matched analysis.
conclusionDCB-only angioplasty, for stable angina and predominantly large vessels, is safe compared to DES as part of routine clinical practice, in terms of all-cause mortality and MACE, including unplanned TLR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.